Emtricitabine and Hepatitis b - a phase IV clinical study of FDA data

Summary:

Hepatitis b is reported as a side effect among people who take Emtricitabine (emtricitabine), especially for people who are male, 30-39 old, have been taking the drug for 5 - 10 years also take Dolutegravir, and have Hiv infection.

The phase IV clinical study analyzes which people have Hepatitis b when taking Emtricitabine. It is created by eHealthMe based on reports of 6,373 people who have side effects when taking Emtricitabine from the FDA, and is updated regularly.

What is Emtricitabine?

Emtricitabine has active ingredients of emtricitabine. eHealthMe is studying from 6,391 Emtricitabine users. Check the latest studies of Emtricitabine.

What is Hepatitis b?

Hepatitis b is found to be associated with 519 drugs and 683 conditions by eHealthMe. Check the latest studies of Hepatitis b.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 22, 2026

6,373 people reported to have side effects when taking Emtricitabine.
Among them, 31 people (0.49%) have Hepatitis b.

Among these 31 people:

How long have people been on Emtricitabine when they have Hepatitis b? *

What is the gender of people who have Hepatitis b when taking Emtricitabine? *

female: 30.43 %
male: 69.57 %

What is the age of people who have Hepatitis b when taking Emtricitabine? *

What are other drugs people take besides Emtricitabine? *

Dolutegravir: 11 people, 35.48%
Isentress: 9 people, 29.03%
Ritonavir: 6 people, 19.35%
Tenofovir Disoproxil Fumarate: 6 people, 19.35%
Viread: 5 people, 16.13%
Rilpivirine: 5 people, 16.13%
Tenofovir Alafenamide Fumarate: 4 people, 12.90%
Prezista: 4 people, 12.90%
Darunavir: 4 people, 12.90%
Norvir: 3 people, 9.68%

What are other side effects people have besides Hepatitis b? *

Diarrhea: 4 people, 12.90%
Drug Resistance (reduction in effectiveness of a drug): 4 people, 12.90%
Itching: 3 people, 9.68%
Drug Ineffective: 3 people, 9.68%
Chronic Kidney Disease: 3 people, 9.68%
Genotype Drug Resistance Test Positive: 3 people, 9.68%
Blood Hiv Rna Increased: 3 people, 9.68%
Hepatic Function Abnormal: 3 people, 9.68%
Hepatitis B Dna Increased: 3 people, 9.68%
Dehydration (dryness resulting from the removal of water): 3 people, 9.68%

What are the existing conditions these people have? *

Hiv Infection: 17 people, 54.84%
Herpes Dermatitis (skin inflammation caused by a herpes simplex virus (hsv)): 3 people, 9.68%
Tuberculosis (a bacterial infection by mycobacterium tuberculosis): 2 people, 6.45%
Hepatitis D: 2 people, 6.45%
Oesophageal Candidiasis (fungal infection of oesophagus): 1 person, 3.23%
Hepatitis C: 1 person, 3.23%
Hepatic Cirrhosis (chronic liver disease characterized by replacement of liver tissue by fibrosis, scar tissue): 1 person, 3.23%
Haemorrhoids (a swollen vein or group of veins in the region of the anus): 1 person, 3.23%
Coronary Heart Disease (narrowing or blockage of the coronary arteries): 1 person, 3.23%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 1 person, 3.23%

* Approximation only. Some reports may have incomplete information.

Do you take Emtricitabine and have Hepatitis b?

- Check whether Hepatitis b is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Emtricitabine:

Emtricitabine (6,391 reports)

Hepatitis b treatments and more:

Hepatitis b (21,088 reports)

Browse all side effects of Emtricitabine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatitis b:

Hepatitis b (519 drugs)

Browse all the conditions that are associated with Hepatitis b:

Hepatitis b (683 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on emtricitabine (the active ingredients of Emtricitabine) and Emtricitabine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.